US Broker Ratings

GeneDx Holdings Corp. (WGS) Stock Analysis: Navigating Growth with a 45.6% Revenue Surge

GeneDx Holdings Corp. (NASDAQ: WGS), a prominent player in the diagnostics and research industry, is capturing investor attention with its impressive 45.6% revenue growth in the past year. This Connecticut-based..

HUTCHMED (China) Limited (HCM) Stock Analysis: Exploring a 49% Potential Upside in the Healthcare Sector

Investors eyeing the healthcare sector may find HUTCHMED (China) Limited (HCM) an intriguing opportunity, particularly given the stock’s potential upside of nearly 49.29%. Headquartered in Hong Kong, HUTCHMED operates within..

Organon & Co. (OGN) Stock Analysis: Exploring a 40.69% Potential Upside Amidst Healthcare Sector Challenges

Organon & Co. (NYSE: OGN), a prominent player in the healthcare sector, operates within the general drug manufacturing industry, offering a diverse portfolio of prescription therapies and medical devices. Headquartered..

Merus N.V. (MRUS) Stock Analysis: A Promising Biotech with 2.71% Upside Potential

Merus N.V. (NASDAQ: MRUS) has recently captured investor attention with its notable presence in the biotechnology sector. Headquartered in Utrecht, Netherlands, Merus is a clinical-stage immuno-oncology company specializing in the..

Metsera, Inc. (MTSR) Stock Analysis: A Biotech Player with 4.82% Potential Upside

Metsera, Inc. (NASDAQ: MTSR) is carving a niche in the competitive biotechnology sector with its innovative approach to tackling obesity and related metabolic disorders. Despite being a relatively new entrant,..

Apellis Pharmaceuticals (APLS) Stock Analysis: A 40% Upside Potential for Investors

Investors in the biotechnology sector are always on the lookout for promising opportunities, and Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) is garnering significant attention. With a market capitalization of $3.42 billion,..

Zai Lab Limited (ZLAB): Investor Outlook and 92.79% Upside Potential in the Biotech Sector

Zai Lab Limited (NASDAQ: ZLAB), a prominent player in the biotechnology sector, offers investors an intriguing opportunity with a potential upside of 92.79%. Headquartered in Pudong, China, Zai Lab focuses..

Alignment Healthcare, Inc. (ALHC) Stock Analysis: Navigating Growth with a 49% Revenue Surge

Alignment Healthcare, Inc. (NASDAQ: ALHC) is making waves in the healthcare industry with its innovative approach to senior care. Operating a consumer-centric platform, it focuses on Medicare Advantage plans, aiming..

Surgery Partners, Inc. (SGRY) Stock Analysis: Exploring a 47.81% Potential Upside in the Healthcare Sector

Surgery Partners, Inc. (NASDAQ: SGRY) stands out in the healthcare sector with a promising growth trajectory underscored by a significant potential upside of 47.81%. As a key player in the..

Akero Therapeutics, Inc. (AKRO) Stock Analysis: A Biotech Hopeful with a 4% Upside Potential

For investors seeking opportunities in the biotechnology sector, Akero Therapeutics, Inc. (NASDAQ: AKRO) presents a compelling case. With a market capitalization of $4.32 billion and a current stock price of..

Bausch + Lomb Corporation (BLCO) Stock Analysis: Navigating Market Challenges with a 2% Upside Potential

Bausch + Lomb Corporation (NYSE: BLCO), a venerable name in the healthcare sector, is a key player in the medical instruments and supplies industry, specializing in eye health. With a..

Vaxcyte, Inc. (PCVX) Stock Analysis: Unveiling a 131% Potential Upside in Biotech

Vaxcyte, Inc. (PCVX), a pioneering company in the biotechnology sector, is capturing attention with its ambitious vaccine development pipeline and significant potential upside. Headquartered in San Carlos, California, this clinical-stage..

Glaukos Corporation (GKOS) Stock Analysis: A 34.79% Potential Upside Amid Robust Revenue Growth

Investors with a keen eye on the healthcare sector may find Glaukos Corporation (NYSE: GKOS) an intriguing opportunity, especially considering its potential upside of 34.79% based on the average target..

Integer Holdings Corporation (ITGR)

⚠️ No article content returned.

..

Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Investors Eye 39% Potential Upside with Strong Buy Ratings

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a leading biopharmaceutical player in the biotechnology sector, has captured significant attention from investors due to its impressive growth trajectory and promising pipeline of drugs..

BrightSpring Health Services, I (BTSG): Investor Outlook on a 7.64% Upside Potential

BrightSpring Health Services, Inc. (NASDAQ: BTSG), a major player in the healthcare sector, presents an intriguing opportunity for investors seeking exposure to the dynamic field of health information services. With..

Madrigal Pharmaceuticals (MDGL) Stock Analysis: Exploring the 16.75% Upside Potential

Madrigal Pharmaceuticals, Inc. (MDGL), a promising player in the biotechnology sector, has captured the attention of investors with its compelling narrative centered on innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH)...

Avidity Biosciences, Inc. (RNA) Investor Outlook: Strong Buy Ratings Signal 42% Upside Potential

Avidity Biosciences, Inc. (RNA), a promising player in the biotechnology sector, is making waves among investors with its innovative approach to tackling diseases through RNA therapeutics. Headquartered in San Diego,..

Telix Pharmaceuticals Limited (TLX): Investor Outlook with 93% Potential Upside

Telix Pharmaceuticals Limited (TLX), an emerging player in the biotechnology sector, has captured the attention of investors with its robust growth potential and a promising pipeline of radiopharmaceuticals. Headquartered in..

Sarepta Therapeutics (SRPT) Stock Analysis: Biotechnology Innovator with a 3.92% Potential Upside

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leading player in the biopharmaceutical space, continues to capture investor attention with its pioneering work in RNA-targeted therapeutics and gene therapies. Headquartered in Cambridge,..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds